Palbociclib - CAS 571190-30-2
Catalog number: B0084-456204
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H29N7O2
Molecular Weight:
447.543
COA:
Inquire
Targets:
CDK
Description:
Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-456204 5 g $298 In stock
Bulk Inquiry
Synonyms:
PD 0332991; PD0332991; PD-0332991; Ibrance; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
MSDS:
Inquire
InChIKey:
AHJRHEGDXFFMBM-UHFFFAOYSA-N
InChI:
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
Canonical SMILES:
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
1.Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J1, Jimeno A2, Diamond JR1. Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528.
Maintaining cell-cycle control has become a mainstay in treatment for many cancers. Cell-cycle manipulation can be especially valuable in breast cancer tumor cells that will often express hormone receptors that are amenable to anti-hormone receptor-targeted therapies. Despite these treatments, patients often progress, leading to other targeted agents being investigated to help promote progression-free survival. Cyclin-dependent kinases (CDKs) have been identified as contributors in the process of cell division. Combining inhibitors of CDKs with traditional endocrine treatments has shown significant progression-free survival in patients with metastatic breast cancer. One such CDK inhibitor, palbociclib, has shown great promise in the treatment of hormone receptor-positive breast cancer. In this article we review the traditional hormonal treatments of breast cancer, how CDK inhibition is beneficial in the treatment of this disease, and the preclinical and clinical data supporting the use of this medication.
2.Isolation and Structural Elucidation of Palbociclib's Eight Process-Related Impurities: Two Identified as New Compounds.
J AOAC Int. 2016 Apr 19. [Epub ahead of print]
Palbociclib is the first U.S. Food and Drug Administration-approved cyclin-dependent kinase inhibitor indicated in combination with letrozole for the treatment of breast cancer. Development of a selective method for the determination of any impurities contained in this drug is significantly important to ensure the quality and safety of palbociclib. In this study, a reliable reversed-phase HPLC method for the separation and determination of eight potential impurities was developed and validated. The structures of two new compounds and six other process-related impurities were characterized and confirmed by MS, NMR, and IR. Based on spectral analysis and available knowledge of the synthetic route of palbociclib, these two new compounds were designated as 6-acetyl-8-cyclopentyl-5-methyl-2-{[3-(piperazin-1-yl)pyridin-2yl]amino}pyrido [2,3-d]pyrimidin-7(8H)-one and 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(4-t-butyloxycarbonyl-)-(piperazin-1-yl)pyridin-2yl]amino}pyrido [2,3-d]pyrimidin-7(8H)-one.
3.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Uras IZ1, Walter GJ2, Scheicher R1, Bellutti F1, Prchal-Murphy M1, Tigan AS1, Valent P3, Heidel FH4, Kubicek S5, Scholl C6, Fröhling S7, Sexl V8. Blood. 2016 Apr 20. pii: blood-2015-11-683581. [Epub ahead of print]
Up to 30% of patients with acute myeloid leukemia (AML) have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase. Such mutations are associated with a poor prognosis and a high propensity to relapse after remission. FLT3 inhibitors are being developed as targeted therapy forFLT3-ITD+AML; however, their use is complicated by rapid development of resistance, illustrating the need for additional therapeutic targets. We show that the FDA-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells. The effect is specific forFLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of theFLT3andPIM1genes, another important leukemogenic driver. There CDK6 regulates transcription in a kinase-dependent manner. Of potential clinical relevance combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity.
4.Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA1, Schwartz GK2, Keohan ML1, D'Angelo SP1, Gounder MM1, Chi P1, Antonescu CR3, Landa J4, Qin LX5, Crago AM6, Singer S6, Koff A7, Tap WD1. JAMA Oncol. 2016 Apr 28. doi: 10.1001/jamaoncol.2016.0264. [Epub ahead of print]
Importance: More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification. The selective CDK4 and CDK6 inhibitor palbociclib inhibits growth and induces senescence in liposarcoma cell lines and xenografts. Our prior phase 2 study demonstrated that treatment with palbociclib (200 mg daily for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects. It is important to understand whether palbociclib at a new dose and schedule-125 mg daily for 21 days every 28 days-results in clinical benefit and manageable toxic effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CAS 571190-30-2 Palbociclib

Palbociclib
(CAS: 571190-30-2)

Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-depen...

CAS 942425-68-5 PHA-767491 hydrochloride

PHA-767491 hydrochloride
(CAS: 942425-68-5)

PHA-767491 hydrochloride is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor, which prevents initiation of DNA replication. It inhibits cell proliferation in ...

CAS 220792-57-4 Aminopurvalanol A

Aminopurvalanol A
(CAS: 220792-57-4)

Aminopurvalanol A is a selective, cell-permeable, reversible and ATP-competitive cyclin-dependent kinase (CDK) inhibitor. It is a 2,6,9-trisubstituted purine an...

CAS 827022-32-2 Palbociclib HCl

Palbociclib HCl
(CAS: 827022-32-2)

Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...

CAS 1431697-85-6 AT7519 trifluoroacetate

AT7519 trifluoroacetate
(CAS: 1431697-85-6)

AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3β (IC50 =...

CAS 741713-40-6 R547

R547
(CAS: 741713-40-6)

R547 is orally bioavailable diaminopyrimidine cyclin-dependent kinase inhibitor (CDKI) with potential antineoplastic activity. CDKI R547 selectively binds to an...

CDK9-IN-6
(CAS: 1391855-95-0)

CDK9-IN-6, one of the CDK9 inhibitors, probably have potential activity in influencing cell cycle of T-type cells.

CAS 827022-33-3 Palbociclib Isethionate

Palbociclib Isethionate
(CAS: 827022-33-3)

Palbociclib is a potent Cdk4/6 inhibitor.

Chemical Structure

CAS 571190-30-2 Palbociclib

Quick Inquiry

Verification code

Featured Items